AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 813411 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 32
Study 813411 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 32
Study 813411 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacrynic acid
Number of subjects: 32
Study 29508236 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge myocardial infarction (PDMI)
Number of subjects: 30051
Study 29508236 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak CK ratio < 3
Number of subjects: 30051
Study 29508236 — intervention group
Group type: COMPARATOR
Intervention: No PDMI
Number of subjects: 30051
Study 27333986 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic heart failure management program including telemonitoring, 24-h information hotline, and patient education.
Number of subjects: 465
Study 24925671 — intervention group
Group type: EXPERIMENTAL
Intervention: Talux foot (K3)
Number of subjects: 10
Study 24925671 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprio-Foot (microprocessor ankle)
Number of subjects: 10
Study 24925671 — intervention group
Group type: COMPARATOR
Intervention: Solid ankle cushion heel foot
Number of subjects: 10
Study 23102611 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 7376
Study 21813328 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplementation rich in arginine (peanuts, equivalent to 1 g of arginine/day)
Number of subjects: 180
Study 21813328 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplementation rich in arginine (peanuts) in HIV+/TB patients
Number of subjects: 180
Study 21813328 — intervention group
Group type: COMPARATOR
Intervention: Low arginine content supplementation (wheat crackers)
Number of subjects: 180
Study 19380449 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg/day) plus Letrozole (2.5 mg/day)
Number of subjects: 270
Study 19380449 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Letrozole (2.5 mg/day)
Number of subjects: 270
Study 17050503 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lisinopril
Number of subjects: 26
Study 17050503 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg losartan
Number of subjects: 26
Study 17050503 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lisinopril plus 50 mg losartan
Number of subjects: 26
Study 17050503 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study 14524646 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study 14524646 — intervention group
Group type: EXPERIMENTAL
Intervention: ARBs
Number of subjects: 0
Study 16786660 — intervention group
Group type: EXPERIMENTAL
Intervention: deprim
Number of subjects: 32
Study 9066355 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA‐DRB1*15+ individuals
Number of subjects: 358
Study 9066355 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA‐DRB1*03+ individuals
Number of subjects: 358
Study 9066355 — intervention group
Group type: EXPERIMENTAL
Intervention: TCRB gene polymorphisms
Number of subjects: 358
Study 9066355 — intervention group
Group type: EXPERIMENTAL
Intervention: TCRBV6S3 allele inheritance in DRB1*03+ individuals
Number of subjects: 358
Study 9066355 — intervention group
Group type: COMPARATOR
Intervention: TCRBV6S1/TCRBV6S3 elements linkage disequilibria
Number of subjects: 358
Study 8117641 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1% ophthalmic solution
Number of subjects: 32
Study 8117641 — intervention group
Group type: COMPARATOR
Intervention: Placebo vehicle
Number of subjects: 32
Study 3534629 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg b.i.d. for 4 weeks
Number of subjects: 50
Study 3534629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31623878 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble contrast (WSC) challenge
Number of subjects: 283
Study 29599089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer message
Number of subjects: 762
Study 29599089 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC message
Number of subjects: 762
Study 29599089 — intervention group
Group type: COMPARATOR
Intervention: Control message
Number of subjects: 762
Study 27399197 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg bd
Number of subjects: 322
Study 27399197 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 322
Study 27399197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 25240207 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (N=24)
Number of subjects: 48
Study 25240207 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=24)
Number of subjects: 48
Study 22275257 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein (10mg/kg/day)
Number of subjects: 30
Study 22275257 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study 20964867 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly oral ibandronate (150 mg)
Number of subjects: 40
Study 20964867 — intervention group
Group type: COMPARATOR
Intervention: Placebo with daily 1-hydroxycholecalciferol (Alfacalcidol; 1 μg) and calcium supplement
Number of subjects: 40
Study 17101256 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol 340 (Niopam)
Number of subjects: 1985
Study 17101256 — intervention group
Group type: COMPARATOR
Intervention: iomeprol 350 (Iomeron)
Number of subjects: 1985
Study 12584032 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day; n = 20)
Number of subjects: 148
Study 12584032 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta estradiol (50 microg/day; n = 39)
Number of subjects: 148
Study 12584032 — intervention group
Group type: COMPARATOR
Intervention: Urinary CTX (C-terminal cross-linking type I collagen)
Number of subjects: 148
Study 10646147 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone IOL (AMO SI‐30NB)
Number of subjects: 40
Study 10646147 — intervention group
Group type: COMPARATOR
Intervention: PMMA IOL (Pharmacia 812A)
Number of subjects: 40
Study 9301412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of 14 g inulin added to a low-fat spread
Number of subjects: 64
Study 9301412 — intervention group
Group type: COMPARATOR
Intervention: Control period (no inulin)
Number of subjects: 64
Study 7687716 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms)
Number of subjects: 18
Study 7687716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3521207 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 36
Study 3521207 — intervention group
Group type: COMPARATOR
Intervention: Low-dose streptokinase (SK) combined with low-dose heparin
Number of subjects: 36
Study 3521207 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Heparin and Low-dose SK)
Number of subjects: 36
Study 3521207 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot volumetry
Number of subjects: 36
Study 29797503 — intervention group
Group type: EXPERIMENTAL
Intervention: Allulose 10 g
Number of subjects: 24
Study 29797503 — intervention group
Group type: EXPERIMENTAL
Intervention: Allulose 5 g
Number of subjects: 24
Study 29797503 — intervention group
Group type: COMPARATOR
Intervention: Fructose (any dose)
Number of subjects: 24
Study 29797503 — intervention group
Group type: EXPERIMENTAL
Intervention: Allulose (5 g, 10 g, pooled doses)
Number of subjects: 24
Study 27285349 — intervention group
Group type: EXPERIMENTAL
Intervention: P5: 4×6×5 s sprints
Number of subjects: 16
Study 27285349 — intervention group
Group type: COMPARATOR
Intervention: P240: 4×4 min at 80% VIFT
Number of subjects: 16
Study 27285349 — intervention group
Group type: COMPARATOR
Intervention: P120: 7×2 min at 85% VIFT
Number of subjects: 16
Study 27285349 — intervention group
Group type: COMPARATOR
Intervention: P30: 2×10×30 s at 90% VIFT
Number of subjects: 16
Study 27285349 — intervention group
Group type: COMPARATOR
Intervention: P15: 3×9×15 s at 95% VIFT
Number of subjects: 16
Study 24438561 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Force (40 g)
Number of subjects: 20
Study 24438561 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy Force (120 g)
Number of subjects: 20
Study 24438561 — intervention group
Group type: COMPARATOR
Intervention: Control (no force)
Number of subjects: 20
Study 22394412 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic treatment (group I)
Number of subjects: 40
Study 22394412 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic and vasodilator treatment (group II)
Number of subjects: 40
Study 22394412 — intervention group
Group type: COMPARATOR
Intervention: Stable COPD (control group)
Number of subjects: 40
Study 19946793 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 0
Study 19946793 — intervention group
Group type: COMPARATOR
Intervention: Control (dry keeping method)
Number of subjects: 0
Study 18243665 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of interferon-gamma (rIFN-gamma or nIFN-gamma) and narrowband UVB (NB-UVB)
Number of subjects: 15
Study 18243665 — intervention group
Group type: COMPARATOR
Intervention: Narrowband UVB (NB-UVB) monotherapy
Number of subjects: 15
Study 16155867 — intervention group
Group type: COMPARATOR
Intervention: T(1rho) imaging method
Number of subjects: 19
Study 12964857 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO2 therapy (5 sessions of breathing 95% oxygen at 2.5 atm abs for 100 min)
Number of subjects: 16
Study 12964857 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO2 therapy
Number of subjects: 16
Study 12964857 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 16
Study 10932430 — intervention group
Group type: EXPERIMENTAL
Intervention: IPD meta-analyses with statistically significant results
Number of subjects: 0
Study 10932430 — intervention group
Group type: COMPARATOR
Intervention: IPD meta-analyses with nonsignificant results
Number of subjects: 0
Study 8871872 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy at a dose of 5 MU subcutaneously three times weekly for 6 months
Number of subjects: 57
Study 8871872 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy
Number of subjects: 57
Study 1518433 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous (SC) octreotide infusion
Number of subjects: 25
Study 1518433 — intervention group
Group type: COMPARATOR
Intervention: Octreotide injection
Number of subjects: 25
Study 1518433 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide treatment
Number of subjects: 25
Study 6378615 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1 mg BID, dose increased biweekly)
Number of subjects: 8
Study 6378615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30950431 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HCV antibody testing
Number of subjects: 3679
Study 30950431 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV RNA detection
Number of subjects: 3679
Study 30950431 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted odds of testing positive for anti-HCV antibody
Number of subjects: 3679
Study 30950431 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV subtype characterization
Number of subjects: 3679
Study 30007559 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartWare HVAD System (n = 308)
Number of subjects: 465
Study 30007559 — intervention group
Group type: COMPARATOR
Intervention: Control (HeartMate II) (n = 157)
Number of subjects: 465
Study 26821868 — intervention group
Group type: EXPERIMENTAL
Intervention: MESSAGE Communication Strategies in Dementia training
Number of subjects: 38
Study 26821868 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 24343353 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR)
Number of subjects: 20
Study 24343353 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 22802322 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib induction (PAD)
Number of subjects: 827
Study 22802322 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib maintenance (PAD)
Number of subjects: 827
Study 22802322 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib induction and maintenance (PAD)
Number of subjects: 827
Study 22802322 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib in high-risk patients
Number of subjects: 827
Study 22802322 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib in patients with deletion 17p13
Number of subjects: 827
Study 19606675 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin administration for 3 months in patients with functional dyspepsia and H. pylori infection (n=30)
Number of subjects: 80
Study 19606675 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin administration for 3 months in patients with functional dyspepsia without H. pylori infection (n=30)
Number of subjects: 80
Study 19606675 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects, n=20)
Number of subjects: 80
Study 17617914 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care
Number of subjects: 2015
Study 17617914 — intervention group
Group type: EXPERIMENTAL
Intervention: Current standard of care plus nursing support
Number of subjects: 2015
Study 17617914 — intervention group
Group type: EXPERIMENTAL
Intervention: Current standard of care plus a paraprofessional home visitor
Number of subjects: 2015
Study 12895685 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microl of Salvia lavandulaefolia essential oil
Number of subjects: 44
Study 12895685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10770464 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-controlled trials (PCTs)
Number of subjects: 296
Study 10770464 — intervention group
Group type: COMPARATOR
Intervention: Comparator-controlled trials (CCTs)
Number of subjects: 296
Study 10770464 — intervention group
Group type: EXPERIMENTAL
Intervention: Latest placebo-controlled trials (PCTs)
Number of subjects: 296
Study 8869897 — intervention group
Group type: COMPARATOR
Intervention: UV‐A1 irradiation (60kJ/m2, 340‐400 nm) for three weeks, five days a week
Number of subjects: 26
Study 8869897 — intervention group
Group type: EXPERIMENTAL
Intervention: UV‐A1 irradiation (progressively decreasing levels) for six weeks, three days a week
Number of subjects: 26
Study 8869897 — intervention group
Group type: COMPARATOR
Intervention: Visible light (> 430 nm) for three weeks
Number of subjects: 26
Study 8869897 — intervention group
Group type: EXPERIMENTAL
Intervention: UV‐A1 irradiation (six weeks, three days a week)
Number of subjects: 26
Study 8869897 — intervention group
Group type: EXPERIMENTAL
Intervention: UV‐A1 irradiation (twice- and once-weekly)
Number of subjects: 26
Study 8869897 — intervention group
Group type: EXPERIMENTAL
Intervention: UV‐A1 irradiation
Number of subjects: 26
Study 1740065 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient bowel preparation
Number of subjects: 100
Study 1740065 — intervention group
Group type: COMPARATOR
Intervention: Inpatient bowel preparation
Number of subjects: 100
Study 6655288 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue 2 vaccine (0.5 ml, doses of 10(1.8)‐10(5.5) plaque-forming units)
Number of subjects: 38
Study 31185041 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% betamethasone valerate ointment applied twice a day after washing or bathing by parents
Number of subjects: 0
Study 29066841 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting cardiovascular mortality risk
Number of subjects: 1378
Study 25569028 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose barium impaction therapy
Number of subjects: 54
Study 25569028 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 54
Study 23855764 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+ (n = 42)
Number of subjects: 81
Study 23855764 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON, n = 39)
Number of subjects: 81
Study 21791651 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir/zidovudine/lamivudine (PI group)
Number of subjects: 530
Study 21791651 — intervention group
Group type: COMPARATOR
Intervention: abacavir/zidovudine/lamivudine (NRTI group)
Number of subjects: 530
Study 19822100 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hyposensitization therapy with low doses of nickel
Number of subjects: 67
Study 16421461 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (400 mg/day up-titrated from 100 mg/day over 1 week)
Number of subjects: 20
Study 16421461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16421461 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 20
Study 16791717 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy follow-up program
Number of subjects: 112
Study 16791717 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 112
Study 10549447 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone-releasing vaginal ring (PVR)
Number of subjects: 547
Study 10549447 — intervention group
Group type: COMPARATOR
Intervention: Copper T 380A IUD (T-Cu)
Number of subjects: 547
Study 8896646 — intervention group
Group type: EXPERIMENTAL
Intervention: OCP users
Number of subjects: 21
Study 8896646 — intervention group
Group type: COMPARATOR
Intervention: Ovulatory women
Number of subjects: 21
Study 8896646 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 21
Study 1725028 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (2.5, 5, or 10 mg once daily)
Number of subjects: 0
Study 1725028 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (5, 10, or 20 mg once daily)
Number of subjects: 0
Study 6129368 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (six 4-litre plasma exchanges over a 2-week period)
Number of subjects: 20
Study 6129368 — intervention group
Group type: COMPARATOR
Intervention: Control procedure (seemingly identical to plasma exchange)
Number of subjects: 20
Study 6129368 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange and Control groups
Number of subjects: 20
Study 31915029 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Protocols Handbook
Number of subjects: 84
Study 31915029 — intervention group
Group type: COMPARATOR
Intervention: Current resuscitation guidelines without the handbook
Number of subjects: 84
Study 31011797 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG3350 + E
Number of subjects: 156
Study 31011797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 29320971 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (verbal and printed nutritional instructions once per month for nine months)
Number of subjects: 31
Study 29320971 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutritional intervention)
Number of subjects: 31
Study 27266883 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping added to physical therapy (exercise and manual therapy)
Number of subjects: 148
Study 27266883 — intervention group
Group type: COMPARATOR
Intervention: Control group (physical therapy only)
Number of subjects: 148
Study 24792382 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) treatment
Number of subjects: 189
Study 24792382 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 189
Study 22698852 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body strength training program
Number of subjects: 22
Study 22698852 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific upper-body strength training program
Number of subjects: 22
Study 20926996 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasocitinib (15 mg or 30 mg twice daily)
Number of subjects: 17
Study 20926996 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 17
Study 18414066 — intervention group
Group type: EXPERIMENTAL
Intervention: High salt diet (3.86 g, 168 mmol/24 hours sodium)
Number of subjects: 21
Study 18414066 — intervention group
Group type: COMPARATOR
Intervention: Low salt diet (1.3 g, 56 mmol/24 hours sodium)
Number of subjects: 21
Study 18414066 — intervention group
Group type: COMPARATOR
Intervention: Plasma 24,25-dihydroxyvitamin D concentrations
Number of subjects: 21
Study 15812738 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured educational/counseling sessions by telephone
Number of subjects: 64
Study 15812738 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured educational/counseling sessions in clinic
Number of subjects: 64
Study 15812738 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 64
Study 12459399 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (0.625 mg) plus medroxyprogesterone acetate (2.5 mg) daily
Number of subjects: 2763
Study 12459399 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 2763
Study 10488696 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-RNA positive patients
Number of subjects: 45
Study 10488696 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher present age
Number of subjects: 45
Study 8945026 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR mode
Number of subjects: 63
Study 8945026 — intervention group
Group type: COMPARATOR
Intervention: DDD mode
Number of subjects: 63
Study 1760824 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (IS-5-MN) 2 x 40 mg/day
Number of subjects: 20
Study 1760824 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (AT) 100 mg/day
Number of subjects: 20
Study 1760824 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of IS-5-MN and AT
Number of subjects: 20
Study 1760824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31767518 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg at Weeks 0, 2, 4, and 6, followed by placebo at Week 8, alirocumab at Week 10, placebo at Weeks 12 and 14.
Number of subjects: 23
Study 31767518 — intervention group
Group type: COMPARATOR
Intervention: Placebo at Week 8, followed by alirocumab at Week 10, placebo at Weeks 12 and 14.
Number of subjects: 23
Study 31767518 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg.
Number of subjects: 23